Prostate cancer prognostic biomarkers are few. However, clinical problems have been reported in discriminating between aggressive and non-aggressive cancers. The goal of this study is to find a more sensitive and specific PCa biomarker that can offer significant information for disease diagnosis and therapy is critical. Sox2 is a transcription factor that belongs to the SOX family and It’s thought to be a potential biomarker for predicting the clinical progression and prognosis of some cancer types. However, its role in prostate cancer is uncertain. Immunohistochemistry was used to examine nuclear and cytoplasmic Sox2 staining in benign (40) and malignant (76) prostate samples. Nuclear and cytoplasmic Sox2 immunostaining was increased significantly in prostate cancer compared to benign prostate tissues. Nuclear Sox2 staining was significantly associated with poorly differentiated Gleason scores and advanced stages. Cytoplasmic Sox2 was only associated with tumor size. This finding suggests that Sox2 may promote cancer progression or aggressiveness. An additional study is also needed to better understand its function and establish whether it might be used as a prostate cancer biomarker.